ZA200907084B - Compositions and methods for preventing and treating mucositis and weight loss - Google Patents

Compositions and methods for preventing and treating mucositis and weight loss

Info

Publication number
ZA200907084B
ZA200907084B ZA200907084A ZA200907084A ZA200907084B ZA 200907084 B ZA200907084 B ZA 200907084B ZA 200907084 A ZA200907084 A ZA 200907084A ZA 200907084 A ZA200907084 A ZA 200907084A ZA 200907084 B ZA200907084 B ZA 200907084B
Authority
ZA
South Africa
Prior art keywords
compositions
preventing
methods
weight loss
treating mucositis
Prior art date
Application number
ZA200907084A
Other languages
English (en)
Inventor
Patrick T Prendergast
Original Assignee
Patrick T Prendergast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrick T Prendergast filed Critical Patrick T Prendergast
Publication of ZA200907084B publication Critical patent/ZA200907084B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200907084A 2007-03-12 2009-10-12 Compositions and methods for preventing and treating mucositis and weight loss ZA200907084B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0704718.6A GB0704718D0 (en) 2007-03-12 2007-03-12 Compounds and methods for preventing and treating mucositis

Publications (1)

Publication Number Publication Date
ZA200907084B true ZA200907084B (en) 2010-06-30

Family

ID=37988800

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200907084A ZA200907084B (en) 2007-03-12 2009-10-12 Compositions and methods for preventing and treating mucositis and weight loss

Country Status (9)

Country Link
US (4) US20100092547A1 (fr)
EP (1) EP2134347A2 (fr)
KR (2) KR20120101153A (fr)
CN (2) CN102600200A (fr)
CA (1) CA2718152C (fr)
GB (1) GB0704718D0 (fr)
TW (1) TW200938196A (fr)
WO (1) WO2008110585A2 (fr)
ZA (1) ZA200907084B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
FR2979241B1 (fr) 2011-08-30 2014-05-09 Nutrialys Medical Nutrition Sa Utilisation de compositions a faible teneur en polyamines dans la prevention ou le traitement des effets indesirables lies a un traitement anti-cancereux
CN104407758A (zh) * 2014-12-04 2015-03-11 合肥鑫晟光电科技有限公司 电容式触控面板及显示装置
CN205384593U (zh) * 2016-03-04 2016-07-13 合肥鑫晟光电科技有限公司 触摸屏及设备
EP3509641A1 (fr) 2016-09-12 2019-07-17 ST IP Holding AG Formulations de 4-méthyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, formulations à goût modifié, et leurs procédés de fabrication et d'utilisation
WO2018047002A1 (fr) 2016-09-12 2018-03-15 St Ip Holding Ag Formulations de 4-méthyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, formulations à goût modifié, et leurs procédés de fabrication et d'utilisation
JP2019531344A (ja) 2016-09-12 2019-10-31 エスティー アイピー ホールディング エージー ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法
WO2018047013A1 (fr) 2016-09-12 2018-03-15 St Ip Holding Ag Formulations de 4-méthyl-5-(pyrazine-2-yl)-3 h-1,2-dithiole-3-thione, et leurs procédés de fabrication et d'utilisation
EP3762104A2 (fr) * 2018-03-07 2021-01-13 ST IP Holding AG Compositions et thérapies combinées comprenant de la 4-méthyl-5-(pyrazin-2-yl) -3h -1,2-dithiole-3-thione, et procédés de fabrication et d'utilisation associés
EP3853223B1 (fr) * 2018-09-18 2025-01-01 ST IP Holding AG Isomères rotamères de 4-alkyl-5-hétéroaryl-3h-1,2-dithiole-3-thiones
WO2021186244A1 (fr) * 2020-03-16 2021-09-23 St Ip Holding Ag Isomères rotamères de 4-alkyl-5-hétéroaryl-3h-1,2-dithiole-3-thiones
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
MX2023000263A (es) 2020-07-16 2023-03-29 Dermavant Sciences GmbH Compuestos isoquinolina y su uso en el tratamiento del desequilibrio de ahr.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1301177C (fr) * 1986-03-05 1992-05-19 Itaru Yamamoto Procede pour la production d'un nouveau derive 1,2-dithiol-3-thione
US5292725A (en) * 1988-08-25 1994-03-08 Prendergast Patrick T Administering particular compounds against various parasites, mycoplasmas, other indications and other infections
AU6676796A (en) * 1995-07-13 1997-02-10 Sloan-Kettering Institute For Cancer Research Compounds, compositions, and methods for inhibiting replication of retroviruses and for inhibiting tumor promoter initiated transcription
AU6462500A (en) * 1999-07-29 2001-02-19 Patrick T. Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
KR20030067935A (ko) * 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
JP2004515453A (ja) 2000-05-05 2004-05-27 ウィスコンシン・アルムナイ・リサーチ・ファウンデーション 癌を化学療法および放射線療法に付する間に細胞を保護するための組成物および方法
AU2002319653A1 (en) * 2001-07-20 2003-03-03 Samir Mitragotri Method for oral drug delivery
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
AU2003296628A1 (en) * 2002-12-19 2004-07-14 Gunther Beisel Agent with a retarded release of substances
GB0308952D0 (en) * 2003-04-17 2003-05-28 St Georges Entpr Ltd Method
US20050090551A1 (en) * 2003-10-27 2005-04-28 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine for the treatment or prevention of mucositis
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
CA2581076A1 (fr) * 2004-09-14 2006-03-23 Molecular Therapeutics, Inc. Formulation de d-methionine a proprietes biopharmaceutiques ameliorees
TW200640898A (en) * 2005-02-24 2006-12-01 Solvay Pharm Bv Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
EP1719543A1 (fr) * 2005-05-04 2006-11-08 Asan Labs., Ltd. Utilisation d'inhibiteurs d'histone deacetylase pour le traitement de problèmes gastro-intestinaux
US8076311B2 (en) * 2006-05-11 2011-12-13 Prendergast Patrick T Compositions and methods for modulating the immune system

Also Published As

Publication number Publication date
CN101264083A (zh) 2008-09-17
EP2134347A2 (fr) 2009-12-23
KR20120101153A (ko) 2012-09-12
GB0704718D0 (en) 2007-04-18
CA2718152C (fr) 2018-08-28
US20180311237A1 (en) 2018-11-01
US20150031701A1 (en) 2015-01-29
US20130259930A1 (en) 2013-10-03
WO2008110585A2 (fr) 2008-09-18
TW200938196A (en) 2009-09-16
CN102600200A (zh) 2012-07-25
US20100092547A1 (en) 2010-04-15
CA2718152A1 (fr) 2008-09-18
KR20090130187A (ko) 2009-12-18
WO2008110585A3 (fr) 2009-03-05

Similar Documents

Publication Publication Date Title
HUS2300001I1 (hu) Készítmények és alkalmazások szklerózis multiplex kezelésére
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
IL202015A0 (en) Methods and compositions for treating skin conditions
ZA201001300B (en) Antigen-asjuvant compositions and methods
EP2120561A4 (fr) Compositions pour traiter des biofilms, et procédés pour leur utilisation
IL210153A0 (en) Nutrigenomics methods and compositions
LT2137210T (lt) Naujas būdas ir kompozicijos
IL212822A0 (en) Anti-cxcr1 compositions and methods
IL196465A0 (en) Compositions and methods for the treatment of mucositis
IL210097A0 (en) Compositions and methods for treating unfluenza
SI2520295T1 (sl) Postopki za preprečevanje in zdravljenje mukozitisa
GB0819530D0 (en) Methods and compositions
ZA200900140B (en) Methods and compositions for treating biofilms
GB0704718D0 (en) Compounds and methods for preventing and treating mucositis
GB0721291D0 (en) Methods and compositions
EP2037941A4 (fr) Compositions de cobalamine et procédés destinés au traitement ou à la prévention de mucosite
IL211204A0 (en) Mucoadherents compositions and their use
SI2061458T1 (sl) Sestavki topiramata in metode za njihovo uporabo
GB0719526D0 (en) Compositions and methods
EP2127647A4 (fr) Composition permettant d'inhiber les dommages musculaires
EP2424549A4 (fr) Compositions et méthodes de traitement et de prévention des lithiases urinaires et des affections associées
GB0811250D0 (en) Methods and compositions
HUE059591T2 (hu) Készítmények és alkalmazások szklerózis multiplex kezelésére
GB0717683D0 (en) Compositions and methods
GB0724549D0 (en) Compositions and methods